Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $275

Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $256 to $275.